Another Study From ImClone Shows Mixed Results for Erbitux
ORLANDO, Fla. -- ImClone Systems (IMCL Quote) released results Sunday from a late-stage clinical trial for its experimental cancer drug, Erbitux, that showed some positive trends, but that nonetheless, failed to meet the study's predefined clinical goal.
The data from the phase III study of 123 patients with advanced head and neck cancer were a mixed bag. The good news: Patients responded to Erbitux. The bad news: The study was too small to show a statistically significant benefit.
These results are considered the most important test of Erbitux discussed so far because the clinical trial is randomized and controlled, or more scientifically rigorous than previous Erbitux studies. This clinical trial was also conducted by an outside, independent group -- the Eastern Cooperative Oncology Group. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,308.26 | 1,096.07 | 2,180.05 | 34.87 |
Oil *
73.22
|
|
DOWN
132.86
|
DOWN
13.11
|
DOWN
26.86
|
DOWN
1.09
|
10 Yr
3.49%
SPDR Gold
107.34
|
|
-1.27%
|
-1.18%
|
-1.22%
|
-3.03%
|
Data delayed 20 minutes |
Connect with TheStreet